377 related articles for article (PubMed ID: 26355232)
1. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Lambrechts D; Thienpont B; Thuillier V; Sagaert X; Moisse M; Peuteman G; Pericay C; Folprecht G; Zalcberg J; Zilocchi C; Margherini E; Chiron M; Van Cutsem E
Br J Cancer; 2015 Sep; 113(7):1027-34. PubMed ID: 26355232
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR
Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810
[TBL] [Abstract][Full Text] [Related]
3. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D
J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738
[TBL] [Abstract][Full Text] [Related]
4. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
5. Aflibercept.
Ciombor KK; Berlin J; Chan E
Clin Cancer Res; 2013 Apr; 19(8):1920-5. PubMed ID: 23444216
[TBL] [Abstract][Full Text] [Related]
6. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E
Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509
[TBL] [Abstract][Full Text] [Related]
7. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
[TBL] [Abstract][Full Text] [Related]
8. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
Chung C; Pherwani N
Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M
Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885
[TBL] [Abstract][Full Text] [Related]
10. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J
Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A
Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
Chibaudel B; Bachet JB; André T; Auby D; Desramé J; Deplanque G; Lecaille C; Louvet C; Tournigand C; Lebrun-Ly V; Dauba J; Lledo G; Garcia ML; Dubreuil O; Hamed NB; Meurisse A; Larsen AK; Tijeras-Raballand A; Bonnetain F; De Gramont A
Int J Oncol; 2019 Apr; 54(4):1433-1445. PubMed ID: 30720091
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
Auvray M; Tougeron D; Auclin E; Moulin V; Artru P; Hautefeuille V; Hammel P; Lecomte T; Locher C; Sickersen G; Coriat R; Lecaille C; Vernerey D; Taieb J; Pernot S
Clin Colorectal Cancer; 2020 Mar; 19(1):39-47.e5. PubMed ID: 31648924
[TBL] [Abstract][Full Text] [Related]
15. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
17. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J
Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581
[TBL] [Abstract][Full Text] [Related]
18. Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker
Van Cutsem E; Paccard C; Chiron M; Tabernero J
Clin Cancer Res; 2020 Feb; 26(3):717-725. PubMed ID: 31727675
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
Chong DQ; Manalo M; Imperial M; Teo P; Yong G; Ng M; Tan IB; Choo SP; Chua C
Asia Pac J Clin Oncol; 2016 Sep; 12(3):275-83. PubMed ID: 27075236
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Feliu J; Díez de Corcuera I; Manzano JL; Valladares-Ayerbes M; Alcaide J; García García T; Vera R; Sastre J
Clin Transl Oncol; 2017 Apr; 19(4):498-507. PubMed ID: 27718155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
